192 related articles for article (PubMed ID: 37698534)
1. Integrated clustering signature of genomic heterogeneity, stemness and tumor microenvironment predicts glioma prognosis and immunotherapy response.
Wu Y; Mao M; Wang LJ
Aging (Albany NY); 2023 Sep; 15(17):9086-9104. PubMed ID: 37698534
[TBL] [Abstract][Full Text] [Related]
2. Optimization of cancer immunotherapy through pyroptosis: A pyroptosis-related signature predicts survival benefit and potential synergy for immunotherapy in glioma.
Zeng Y; Cai Y; Chai P; Mao Y; Chen Y; Wang L; Zeng K; Zhan Z; Xie Y; Li C; Zhan H; Zhao L; Chen X; Zhu X; Liu Y; Chen M; Song Y; Zhou A
Front Immunol; 2022; 13():961933. PubMed ID: 35990696
[TBL] [Abstract][Full Text] [Related]
3. Optimized risk stratification strategy for glioma patients based on the feature genes of poor immune cell infiltration patterns.
Wan HT; Su ZJ; Guo ZS; Wen P; Hong XY
J Cancer Res Clin Oncol; 2023 Nov; 149(15):13855-13874. PubMed ID: 37535161
[TBL] [Abstract][Full Text] [Related]
4. Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer.
Zheng H; Liu H; Li H; Dou W; Wang J; Zhang J; Liu T; Wu Y; Liu Y; Wang X
Stem Cell Res Ther; 2022 Jun; 13(1):244. PubMed ID: 35681225
[TBL] [Abstract][Full Text] [Related]
5. Classification related to immunogenic cell death predicts prognosis, immune microenvironment characteristics, and response to immunotherapy in lower-grade gliomas.
Kuang Y; Jiang B; Zhu H; Zhou Y; Huang H; Li C; Zhang W; Li X; Cao Y
Front Immunol; 2023; 14():1102094. PubMed ID: 37153540
[TBL] [Abstract][Full Text] [Related]
6. Construction and validation of an immune infiltration-related risk model for predicting prognosis and immunotherapy response in low grade glioma.
Li J; Guo Q; Xing R
BMC Cancer; 2023 Aug; 23(1):727. PubMed ID: 37543576
[TBL] [Abstract][Full Text] [Related]
7. RNA N1-methyladenosine regulator-mediated methylation modification patterns and heterogeneous signatures in glioma.
Mao M; Chu Q; Lou Y; Lv P; Wang LJ
Front Immunol; 2022; 13():948630. PubMed ID: 35936006
[TBL] [Abstract][Full Text] [Related]
8. Pyroptosis: a novel signature to predict prognosis and immunotherapy response in gliomas.
He G; Chen Z; Zhuo S; Tang J; Hao W; Yang K; Yang C
Hum Cell; 2022 Nov; 35(6):1976-1992. PubMed ID: 36129672
[TBL] [Abstract][Full Text] [Related]
9. Lipid metabolism-related gene signature predicts prognosis and depicts tumor microenvironment immune landscape in gliomas.
Li J; Zhang S; Chen S; Yuan Y; Zuo M; Li T; Wang Z; Liu Y
Front Immunol; 2023; 14():1021678. PubMed ID: 36860853
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of m
Zhao K; Li W; Yang Y; Hu X; Dai Y; Huang M; Luo J; Zhang K; Zhao N
Front Immunol; 2022; 13():955848. PubMed ID: 36203569
[TBL] [Abstract][Full Text] [Related]
11. Identification of an endoplasmic reticulum stress-related signature associated with clinical prognosis and immune therapy in glioma.
Li L; Yang Z; Zheng Y; Chen Z; Yue X; Bian E; Zhao B
BMC Neurol; 2022 May; 22(1):192. PubMed ID: 35614390
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 Pattern Provides a New Scoring System and Predicts the Prognosis and Immune Therapeutic Response in Glioma.
Jiang F; Lu DF; Zhan Z; Yuan GQ; Liu GJ; Gu JY; Sun XO; Wang Z
Cells; 2022 Dec; 11(24):. PubMed ID: 36552760
[TBL] [Abstract][Full Text] [Related]
13. Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour microenvironment in lower-grade glioma.
Cai J; Hu Y; Ye Z; Ye L; Gao L; Wang Y; Sun Q; Tong S; Yang J; Chen Q
Front Immunol; 2022; 13():1011757. PubMed ID: 36325335
[TBL] [Abstract][Full Text] [Related]
14. MAPK signaling pathway-based glioma subtypes, machine-learning risk model, and key hub proteins identification.
Liu H; Tang T
Sci Rep; 2023 Nov; 13(1):19055. PubMed ID: 37925483
[TBL] [Abstract][Full Text] [Related]
15. A pyroptosis-related signature predicts prognosis and indicates immune microenvironment infiltration in glioma.
Chen J; Chen S; Li B; Zhou S; Lin H
Cancer Med; 2023 Feb; 12(4):5071-5087. PubMed ID: 36161280
[TBL] [Abstract][Full Text] [Related]
16. Immune Infiltrating Cells-Derived Risk Signature Based on Large-scale Analysis Defines Immune Landscape and Predicts Immunotherapy Responses in Glioma Tumor Microenvironment.
Zhang N; Zhang H; Wang Z; Dai Z; Zhang X; Cheng Q; Liu Z
Front Immunol; 2021; 12():691811. PubMed ID: 34489938
[TBL] [Abstract][Full Text] [Related]
17. A Novel Immune Gene-Related Prognostic Score Predicts Survival and Immunotherapy Response in Glioma.
Luo X; Wang Q; Tang H; Chen Y; Li X; Chen J; Zhang X; Li Y; Sun J; Han S
Medicina (Kaunas); 2022 Dec; 59(1):. PubMed ID: 36676646
[No Abstract] [Full Text] [Related]
18. An N6-methyladenosine regulation- and mRNAsi-related prognostic index reveals the distinct immune microenvironment and immunotherapy responses in lower-grade glioma.
Tang G; Peng J; Huo L; Yin W
BMC Bioinformatics; 2023 Jun; 24(1):225. PubMed ID: 37264314
[TBL] [Abstract][Full Text] [Related]
19. Integrated analysis based on vesicle trafficking-related genes identifying CNIH4 as a novel therapeutic target for glioma.
Fang Z; Kong F; Zeng J; Zhang Z; Wang Y; Wang Y; Duan J; Chen L; Wang J; Liu F
Cancer Med; 2023 Jun; 12(11):12943-12959. PubMed ID: 37062068
[TBL] [Abstract][Full Text] [Related]
20. Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas.
Li Y; Feng Y; Luo F; Peng G; Li Y
Front Immunol; 2022; 13():1089792. PubMed ID: 36726969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]